Market Insights
Beyond the Price Target: How Nuvation Bio''s Glioma Trial Could Reshape Neuro-Oncology
RBC Capital''s increased price target for Nuvation Bio to $4.00 is more
Nuvation BioNUV-422RBC Capital+7
Market Insights
Beyond Height: How Ascendis Pharma''s TransCon CNP Data Reveals a New Paradigm
Ascendis Pharma's positive 12-month interim data from its Phase 2 ACcomplisH
achondroplasiaTransCon CNPAscendis Pharma+6